Anders Pedersen Net Worth

Mr. Anders Pedersen biography

Anders Pedersen is the Chief Operating Officer at Galecto.

What is the salary of Mr Pedersen?

As the Chief Operating Officer of Galecto, the total compensation of Mr Pedersen at Galecto is $449,659. There are 2 executives at Galecto getting paid more, with Dr. Hans T. Schambye having the highest compensation of $644,982.

How old is Mr Pedersen?

Mr Pedersen is 61, he's been the Chief Operating Officer of Galecto since . There are 1 older and 3 younger executives at Galecto. The oldest executive at Galecto Inc. is Prof. Bertil Lindmark M.D., Ph.D., 66, who is the Chief Medical Officer.

What's Mr Pedersen's mailing address?

Anders's mailing address filed with the SEC is C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N, G7, DK-2200.

Insiders trading at Galecto

Over the last 4 years, insiders at Galecto have traded over $2,298,261 worth of Galecto stock and bought 1,911,769 units worth $28,139,830 . The most active insiders traders include Holdings A/S Novo, Chau Quang Khuong, and Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of $2,037,418. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth $617,010.

What does Galecto do?

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Galecto executives and stock owners

Galecto executives and other stock owners filed with the SEC include:

• Dr. Hans T. Schambye,
  Co-Founder, Pres, CEO & Director
• Prof. Bertil Lindmark M.D., Ph.D.,
  Chief Medical Officer
• Anders Pedersen,
  Chief Operating Officer
• Dr. Stephanie Oestreich Ph.D.,
  Chief Bus. Officer
• Garrett Winslow,
  Sr. VP & Gen. Counsel
• Jonathan P. Freve CPA, CPA,
  Chief Financial Officer
• Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP,
  Co-Founder & Member of the Clinical Advisory Board - IPF
• Dr. Hakon Leffler,
  Co-Founder
• Ulf J. Nilsson,
  Co-Founder
• Advisors Llc Orbi Med Genes...,
  
• Holdings A/S Novo,
  10% owner
• Carl Goldfischer,
  
• Anders Pedersen,
  Chief Operating Officer
• Hans T. Schambye,
  Chief Executive Officer
• Stephan Christgau,
  Director
• Advisors Llc Orbi Med Advis...,
  
• Bertil Lindmark,
  Chief Medical Officer
• Jonathan Freve,
  Chief Financial Officer
• Chau Quang Khuong,
  Director
• Stephanie Oestreich,
  Chief Business Officer
• Jayson Donald Alexander Dallas,
  
• Amit Munshi,
  
• Anne Prener,
  
• David Shapiro,
  
• Garrett Winslow,
  General Counsel